Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1057)	5/5/2000 6:23:00 PM
From: Biomaven	Respond to of 52153

worldlyinvestor.com Fund Talk Mutual Funds Weekly Scorecard: Biotech Bites Back, Bulls Bite Bullet By Emily Burg, Correspondent Biotech funds come back to life, while bull funds take it on the chin. This Week's Shiners Biotech stocks bested broader market trends this week, which helped put funds that hold biotech stocks squarely in the spotlight. Although the Nasdaq shed 1.4% for the week, some bellwether biotech stocks bucked the Nasdaq's negativity and led the sector higher. Four of this week's five top performing funds are biotech funds. Leading the pack is the Franklin Biotech Discovery Fund (Nasdaq:FBDIX - news), up 13.43% for the week. The fund invests in large-cap biotech stocks, but also looks below the radar screen for hot biotech investments. Among its top holdings are biotech stock stars Abgenix (Nasdaq:ABGX - news), Genentech (NYSE:DNA - news), Medimmune (Nasdaq:MEDI - news) and Amgen (Nasdaq:AMGN - news). Coming in at number two is the Fidelity Select Biotechnology Portfolio (Nasdaq:FBIOX - news), up 13.21% for the week. Given the fund's holdings, it's little wonder that performance for the week came in just behind the Franklin fund. The Fidelity fund also holds Amgen, Genentech and Medimmune. Although the Dresdner RCM Biotechnology Fund (Nasdaq:DRBNX - news) also holds these biotech stocks, it came in third for the week, posting a 12.54% gain. However, it's the twelfth best performing mutual fund year-to-date in the Lipper mutual fund universe. Number four this week is the Rydex Biotechnology Fund (Nasdaq:RYOIX - news), up 12.31% for the week. So maybe we'll get the mo-mo players back again, a decidedly mixed blessing. Peter